Ok so from the last quarterly IHL-216A for Concussion and Traumatic Brain Injury is expected to be done, hopefully results soon
and on track
For IHL-675A multi-use drug candidate for Lung Inflammation, Rheumatoid Arthritis, and Inflammatory Bowel Disease, trial should have begun Q4 2021
Results must be due soon based on this:
For IHL-42X for Obstructive Sleep Apnoea the Company has been granted a pre-IND meeting with FDA on May 11. Planning commences for pivotal clinical trials to commence after opening an IND with FDA. So should get feedback this quarter.
For Psilocybin-assisted Psychotherapy for General Anxiety Disorder (Psi-GAD). As per the last quarterly therapist training for the phase 2a trial assessing psilocybin-assisted therapy for Generalised Anxiety Disorder is completed; patient recruitment to commence imminently. So probably not much on this until Q3?
Also - aren't we waiting on a second psychedelics trial to be announced? See here
And they need to explain to us what this acquisition is all about
Plenty of fish to fry in Q2 2022
- Forums
- ASX - By Stock
- General discussion
Ok so from the last quarterly IHL-216A for Concussion and...
-
- There are more pages in this discussion • 6,686 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online